Insider Transactions in Q2 2024 at Processa Pharmaceuticals, Inc. (PCSA)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 05
2024
|
James H Stanker Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
518
-7.8%
|
$1,036
$2.79 P/Share
|
|
Apr 05
2024
|
James H Stanker Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,675
+20.15%
|
-
|
|
Apr 05
2024
|
Sian Bigora Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-1.69%
|
$736
$2.79 P/Share
|
|
Apr 05
2024
|
Sian Bigora Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,675
+7.13%
|
-
|
|
Apr 05
2024
|
Patrick Lin Chief Business - Strategy Off |
SELL
Payment of exercise price or tax liability
|
Direct |
539
-1.84%
|
$1,078
$2.79 P/Share
|
|
Apr 05
2024
|
Patrick Lin Chief Business - Strategy Off |
BUY
Exercise of conversion of derivative security
|
Direct |
1,675
+5.42%
|
-
|
|
Apr 05
2024
|
David Young Pres. Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
518
-0.64%
|
$1,036
$2.79 P/Share
|
|
Apr 05
2024
|
David Young Pres. Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,675
+2.02%
|
-
|
|
Apr 05
2024
|
Wendy Guy Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
368
-3.12%
|
$736
$2.79 P/Share
|
|
Apr 05
2024
|
Wendy Guy Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,675
+12.43%
|
-
|